Literature DB >> 7573585

Clinical effects of recent cocaine use on patients with acute schizophrenia.

M R Serper1, M Alpert, N A Richardson, S Dickson, M H Allen, A Werner.   

Abstract

OBJECTIVE: Dopamine function has been hypothesized to be involved in both producing schizophrenic symptoms and mediating cocaine's reinforcing properties. As a result, cocaine abuse in schizophrenic patients may be seen as a natural experiment that may alter the phenomenology and neurobiology of schizophrenia. This report concerns the clinical effects of cocaine abuse and cessation in schizophrenic patients at two times: when patients presented to the psychiatric emergency service and again after 4 weeks of hospitalization.
METHOD: The subjects were 15 cocaine-abusing and 22 cocaine-abstaining schizophrenic patients. Diagnostic assessments were performed with the Structured Clinical Interview for DSM-III-R--Patient Version, which uses DSM-III-R criteria. All of the patients were assessed at both times with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, and the Scale for the Assessment of Negative Symptoms.
RESULTS: Cocaine-abusing schizophrenic patients showed fewer negative signs and more anxiety/depression at the hospital-admission assessment than their nonabusing counterparts. At retest, no group differences were detected in patients' negative signs or mood symptoms. Severity of positive symptoms was equal at both testing sessions.
CONCLUSIONS: The significant difference in negative signs and mood symptoms at admission assessment was attributed to the neurobiological impact of cocaine. The role of psychostimulants in schizophrenic patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573585     DOI: 10.1176/ajp.152.10.1464

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  8 in total

Review 1.  The psychiatric emergency service: where we've been and where we're going.

Authors:  R E Breslow; B J Erickson; K C Cavanaugh
Journal:  Psychiatr Q       Date:  2000

Review 2.  Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Authors:  David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 3.  Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.

Authors:  Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss
Journal:  J Psychiatr Pract       Date:  2005-09       Impact factor: 1.325

4.  Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia.

Authors:  Thomas Wobrock; Helmut Sittinger; Bernd Behrendt; Roberto D'Amelio; Peter Falkai; Dieter Caspari
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-11-25       Impact factor: 5.270

Review 5.  Psychotic symptoms in patients with medical disorders.

Authors:  Ashwin A Patkar; Rajnish Mago; Prakash S Masand
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

6.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

7.  Comorbid substance abuse and brain morphology in recent-onset psychosis.

Authors:  Thomas Wobrock; Helmut Sittinger; Bernd Behrendt; Roberto D'Amelio; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-02-04       Impact factor: 5.270

8.  Associations between Polygenic Risk for Psychiatric Disorders and Substance Involvement.

Authors:  Caitlin E Carey; Arpana Agrawal; Kathleen K Bucholz; Sarah M Hartz; Michael T Lynskey; Elliot C Nelson; Laura J Bierut; Ryan Bogdan
Journal:  Front Genet       Date:  2016-08-15       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.